Table 3.
Odds ratio (OR) and 95% confidence interval (CI) of clinical status and FUT2 rs281377 genotypic frequencies in 339 HCC patients.
| Variable | Genotypic frequencies | |||
|---|---|---|---|---|
| TT (N = 259) | TC + CC (N = 80) | OR (95% CI) | p-value | |
| HCC Stage | ||||
| I or II | 171 (66.0%) | 51 (63.8%) | 1.00 | 0.709 |
| III or IV | 88 (34.0%) | 29 (36.2%) | 1.105 (0.655-1.865) | |
| Tumor size | ||||
| ≤T2 | 174 (67.2%) | 51 (63.8%) | 1.00 | 0.570 |
| >T2 | 85 (32.8%) | 29 (36.2%) | 1.164 (0.689-1.967) | |
| Lymph node metastasis | ||||
| No | 253 (97.7%) | 75 (93.8%) | 1.00 | 0.083 |
| Yes | 6 (2.3%) | 5 (6.2%) | 2.811 (0.835-9.469) | |
| Distant metastasis | ||||
| No | 246 (95.0%) | 75 (93.8%) | 1.00 | 0.668 |
| Yes | 13 (5.0%) | 5 (6.2%) | 1.262 (0.436-3.653) | |
| Vascular invasion | ||||
| No | 215 (83.0%) | 63 (78.8%) | 1.00 | 0.386 |
| Yes | 44 (17.0%) | 17 (21.2%) | 1.319 (0.705-2.466) | |
| Child-Pugh grade | ||||
| A | 197 (76.1%) | 61 (76.3%) | 1.00 | 0.972 |
| B or C | 62 (23.9%) | 19 (23.7%) | 0.990 (0.549-1.783) | |
| HBsAg | ||||
| Negative | 151 (58.3%) | 47 (58.8%) | 1.00 | 0.943 |
| Positive | 108 (41.7%) | 33 (41.2%) | 0.982 (0.590-1.633) | |
| Anti-HCV | ||||
| Negative | 140 (54.1%) | 37 (46.3%) | 1.00 | 0.222 |
| Positive | 119 (45.9%) | 43 (53.7%) | 1.367 (0.827-2.216) | |
| Liver cirrhosis | ||||
| Negative | 56 (21.6%) | 11 (13.8%) | 1.00 | 0.122 |
| Positive | 203 (78.4%) | 69 (86.2%) | 1.730 (0.858-3.491) | |
The ORs and their 95% CIs were estimated based on logistic regression models. >T2: multiple tumors of >5 cm in diameter or tumor(s) involving a major branch of the portal vein or hepatic veins.